Login
$ARVN
$6.77 -$0.05 (0.73%) Live

$ARVN SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 Form 4: Loomis David K, VP, Chief Accounting Officer

Sold 232 shares ($1.48K)

03 Nov 2026 S-3
03 Nov 2026 10-Q
03 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation –

28 Sep 2026 S-8
22 Sep 2026 144
09 Sep 2026 144
04 Sep 2026 144
31 Aug 2026 S-8
14 Aug 2026 SCHEDULE 13G/A
04 Aug 2026 144
04 Aug 2026 10-Q
04 Aug 2026 8-K: Results of Operations and Financial Condition

– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals –

09 Jul 2026 144
26 Jun 2026 Form 4: Smaldone Alsup Laurie, Director

Received 15,527 shares as a grant or award · Granted 22,714 Stock Option (right to buy)

26 Jun 2026 Form 4: Norwalk Leslie V, Director

Received 15,527 shares as a grant or award · Granted 22,714 Stock Option (right to buy)

26 Jun 2026 Form 4: Morrison Briggs, Director

Received 15,527 shares as a grant or award · Granted 22,714 Stock Option (right to buy)

26 Jun 2026 Form 4: Kennedy Edward Moore Jr., Director

Received 15,527 shares as a grant or award · Granted 22,714 Stock Option (right to buy)

26 Jun 2026 Form 4: Cunningham Everett, Director

Received 15,527 shares as a grant or award · Granted 22,714 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support